GlaxoSmithKline (GSK) has released an update.
GlaxoSmithKline (GSK) has successfully completed the sale of its remaining shares in Haleon, raising approximately £1.248 billion. With the sale of 385,320,110 shares at 324 pence each, GSK has fully exited its position in Haleon, following a series of disposals since the demerger in July 2022 that collectively generated around £3.9 billion.
For further insights into GSK stock, check out TipRanks’ Stock Analysis page.
